Literature DB >> 1632675

Pamidronate associated hallucinations.

D Foley-Nolan, M J Daly, D Williams, A Wasti, M Martin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632675      PMCID: PMC1004791          DOI: 10.1136/ard.51.7.927-d

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

Review 1.  Treatment of Paget's disease of bone.

Authors:  J A Cantrill; D C Anderson
Journal:  Clin Endocrinol (Oxf)       Date:  1990-04       Impact factor: 3.478

2.  Paget's disease of bone treated in five days with AHPrBP (APD) per Os.

Authors:  D Thiébaud; P Jaeger; P Burckhardt
Journal:  J Bone Miner Res       Date:  1987-02       Impact factor: 6.741

3.  Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

Authors:  H I Harinck; S E Papapoulos; H J Blanksma; A J Moolenaar; P Vermeij; O L Bijvoet
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-21

4.  A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.

Authors:  D Thiébaud; P Jaeger; C Gobelet; A F Jacquet; P Burckhardt
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

5.  Clinical experience with pamidronate in the treatment of Paget's disease of bone.

Authors:  S J Gallacher; B F Boyce; U Patel; A Jenkins; S H Ralston; I T Boyle
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

  5 in total
  2 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  Alendronate treatment induces IL-1B expression and apoptosis in glioblastoma cell line.

Authors:  Paola Maura Tricarico; Angeladine Epate; Fulvio Celsi; Sergio Crovella
Journal:  Inflammopharmacology       Date:  2017-06-23       Impact factor: 4.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.